High-dose olanzapine for treatment-refractory schizophrenia

Clinical Neuropharmacology

Volumn 26, Issue 2, 2003, Pages 58-61

  Lerner, Vladimir ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

High dose; Olanzapine; Resistant schizophrenia

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROPRANOLOL; PYRIDOXINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; AKATHISIA; ARTICLE; CASE REPORT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GOOD GENERAL CONDITION; HUMAN; LABORATORY TEST; MALE; MEDICAL LITERATURE; MENTAL HEALTH; PRIORITY JOURNAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

ADULT; BENZODIAZEPINES; FEMALE; HUMANS; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037349614     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200303000-00003     Document Type: Article

References (28)

1. Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient, J Clin Psychiatry 1998; 59(suppl 1): 13-9.
2. Marder SR. Management of treatment- resistant patients with schizophrenia. J Clin Psychiatry 1996;57(suppl 11):26-30.
3. Thompson C. The use of high-dose antipsychotic medication. Br J Psychiatry 1994;164:448-58.
4. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
5. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17: 407-18.
6. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
7. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-7.
8. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663-674.
9. Sheitman BB, Lindgren JC, Early J, et al. High-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 1997;154: 1626. Letter.
10. Reich J. Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry 1999;156:661. Letter.
11. Heimann SW. High-dose olanzapine in an adolescent. J Am Acad Child Adolesc Psychiatry 1999;38:496-8.
12. Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psychopharmacol 1999;19:275-6. Letter.
13. Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psvchiatry 1999;156:158-9.
14. Meisenzahl EM, Dresel S, Frodl T, et al. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol 2000;14: 364-70.
15. Cassidy EM, O'Brien M, Osman MF, et al. Lethal catatonia responding to high-dose olanzapine therapy. J Psychopharmacol 2001;15:302-4.
16. Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-3.
17. Overall JE, Gohram DE. The Brief Psychiatric Rating Scale. Psychol Rep 1961;10:799-812.
18. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatry Scand Suppl 1970;212:11-9.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
20. Bondolfi G, Baumann P, Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur Neuropsychopharmacol 1996;6(suppl 2):21-5.
21. Kane JM. Management strategies for the treatment of schizophrenia. J Clin Psychiatry 1999;60(suppl 12):13-7.
22. Pilowsky LS, Busatto GF, Taylor M, et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-53.
23. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
24. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62: 757-71.
25. Levinson DF, Singh H, Simpson GM. Timing of acute clinical response to fluphenazine. Br J Psychiatry 1992;160:365-71.
26. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999;60(suppl 12):4-8.
27. Bronson BD, Lindenmayer JP. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J Clin Psychopharma- col 2000;20:382-4.
28. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-8.